Distinct mutational landscape between HR plus and HR-HER2+early-stage breast cancer patients.

Chen, B; Liao, N; Zhang, GC; Wang, YL; Chen, XQ; Guo, LP; Cao, L; Mok, H; Ren, CY; Li, K; Jia, MH; Li, C; Wen, LZ; Lin, JL; Wei, GN; Hou, T; Lizaso, A; Liu, J; Balch, CM

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):